Last Posted: Sep 03, 2019
- Medication Use to Reduce Risk of Breast Cancer- US Preventive Services Task Force Recommendation Statement
USPSTF Recommendation, JAMA, September 3, 2019 - Pathogenic Germline Variants in Patients With Metastatic Breast Cancer.
Stuttgen Kelsey et al. JAMA oncology 2019 Aug - Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
Terkelsen Thorkild et al. Familial cancer 2019 Aug - Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson Heidi D et al. JAMA 2019 322(7) 666-685 - Risk versus benefit of chemoprevention among raloxifene and tamoxifen users with a family history of breast cancer.
Anderson Chelsea et al. Cancer prevention research (Philadelphia, Pa.) 2019 Aug - US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.
Newman Lisa et al. JAMA surgery 2019 Aug - Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini Roxana et al. Breast cancer research and treatment 2019 Aug - Precision medicine: PI3K targeting in advanced breast cancer.
Rocca Andrea et al. Breast cancer research and treatment 2019 Aug - Case-Only Analysis of Gene-Environment Interactions Using Polygenic Risk Scores.
Meisner Allison et al. American journal of epidemiology 2019 Aug - Artificial Intelligence Treatment Decision Support For Complex Breast Cancer Among Oncologists With Varying Expertise.
Xu Fengrui et al. JCO clinical cancer informatics 2019 Aug 31-15
.png)
No hay comentarios:
Publicar un comentario